2021
Karo Pharma enters into an agreement for the potential acquisition of the E45® brand from Reckitt
Karo Pharma Aktiebolag (“Karo”) has today entered into a put option agreement pursuant to which it may acquire the dermatology…
Karo Pharma intends to change listing venue to Nasdaq First North Growth Market during the first half of 2022
The board of directors of Karo Pharma Aktiebolag (publ) (the ”Company” or ”Karo”) has resolved to initiate a process to…
Karo Pharma acquires Sylphar International NV for EUR 290m and intends to carry out a rights issue of approximately EUR 200-250m
Karo Pharma Aktiebolag (publ) (the ”Company” or ”Karo”) has today entered into an agreement to acquire all of the shares…
Karo Pharma Quarterly report Q3 2021
July – September Revenues amounted to MSEK 738.5 (679.1), corresponding to an increase of +9% for the period. The organic…
Anna Hale appointed CMO at Karo Pharma
Karo Pharma Aktiebolag (publ) (“Karo”) has appointed Anna Hale as the Chief Marketing Officer (CMO) of Karo. The appointment reflects Karo’s growth ambitions, fueled by a…
Magnus Nylén leaves Karo Pharma, Matt Roberts appointed new CCO
Karo Pharma Aktiebolag (“Karo”) has appointed Matt Roberts as the new Chief Commercial Officer (CCO) of Karo, replacing Magnus Nylén…
Interim report Q2 2021
April – June Revenues amounted to MSEK 747.9 (688.9), corresponding to an increase of +9% for the period. The organic…
Karo Pharma divests brand portfolio to Evolan Pharma
Karo Pharma AB (“Karo”) today announces the divestment of a portfolio consisting of 12 brands to Evolan Pharma AB (“Evolan”).…
Karo Pharma to sell its treasury shares
Karo Pharma (“Karo”) pursues a growth strategy, which combines geographical expansion with an active acquisition strategy. To execute on this…